解决他汀类药物治疗之外的残余风险：血脂异常管理的新目标--欧洲心脏病学会心血管圆桌会议报告

IF 3.6 3区医学 Q2 PHARMACOLOGY & PHARMACY

Journal of clinical lipidology Pub Date : 2024-07-06 DOI:10.1016/j.jacl.2024.07.001

François Mach MD, Frank L.J. Visseren MD, Nilo B. Cater MD, Nejoua Salhi MD, Jarkko Soronen MD, Kausik K. Ray MD, Victoria Delgado MD, J. Wouter Jukema MD, Ulrich Laufs MD, Jose-Luis Zamorano MD, Emilio Ros MD, Jogchum Plat MD, Akos Gabor Gesztes BPharm, Lale Tokgozoglu MD, Chris Packard MD, Peter Libby MD

{"title":"解决他汀类药物治疗之外的残余风险：血脂异常管理的新目标--欧洲心脏病学会心血管圆桌会议报告","authors":"François Mach MD, Frank L.J. Visseren MD, Nilo B. Cater MD, Nejoua Salhi MD, Jarkko Soronen MD, Kausik K. Ray MD, Victoria Delgado MD, J. Wouter Jukema MD, Ulrich Laufs MD, Jose-Luis Zamorano MD, Emilio Ros MD, Jogchum Plat MD, Akos Gabor Gesztes BPharm, Lale Tokgozoglu MD, Chris Packard MD, Peter Libby MD","doi":"10.1016/j.jacl.2024.07.001","DOIUrl":null,"url":null,"abstract":"Cardiovascular (CV) disease is the most common cause of death in Europe. Despite proven benefits, use of lipid-lowering therapy remains suboptimal. Treatment goals are often not achieved, even in patients at high risk with atherosclerotic CV disease (ASCVD).","PeriodicalId":15392,"journal":{"name":"Journal of clinical lipidology","volume":null,"pages":null},"PeriodicalIF":3.6000,"publicationDate":"2024-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Addressing residual risk beyond statin therapy: New targets in the management of dyslipidaemias–A report from the European Society of Cardiology Cardiovascular Round Table\",\"authors\":\"François Mach MD, Frank L.J. Visseren MD, Nilo B. Cater MD, Nejoua Salhi MD, Jarkko Soronen MD, Kausik K. Ray MD, Victoria Delgado MD, J. Wouter Jukema MD, Ulrich Laufs MD, Jose-Luis Zamorano MD, Emilio Ros MD, Jogchum Plat MD, Akos Gabor Gesztes BPharm, Lale Tokgozoglu MD, Chris Packard MD, Peter Libby MD\",\"doi\":\"10.1016/j.jacl.2024.07.001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Cardiovascular (CV) disease is the most common cause of death in Europe. Despite proven benefits, use of lipid-lowering therapy remains suboptimal. Treatment goals are often not achieved, even in patients at high risk with atherosclerotic CV disease (ASCVD).\",\"PeriodicalId\":15392,\"journal\":{\"name\":\"Journal of clinical lipidology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.6000,\"publicationDate\":\"2024-07-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of clinical lipidology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.jacl.2024.07.001\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of clinical lipidology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jacl.2024.07.001","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

摘要

在欧洲，心血管疾病是最常见的死亡原因。尽管降脂治疗的益处已得到证实，但其效果仍不理想。即使是患有动脉粥样硬化性心血管疾病（ASCVD）的高风险患者，也往往达不到治疗目标。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Addressing residual risk beyond statin therapy: New targets in the management of dyslipidaemias–A report from the European Society of Cardiology Cardiovascular Round Table

查看原文本刊更多论文

Addressing residual risk beyond statin therapy: New targets in the management of dyslipidaemias–A report from the European Society of Cardiology Cardiovascular Round Table

Cardiovascular (CV) disease is the most common cause of death in Europe. Despite proven benefits, use of lipid-lowering therapy remains suboptimal. Treatment goals are often not achieved, even in patients at high risk with atherosclerotic CV disease (ASCVD).

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of clinical lipidology 医学-药学

CiteScore

7.00

自引率

6.80%

发文量

209

审稿时长

49 days

期刊介绍： Because the scope of clinical lipidology is broad, the topics addressed by the Journal are equally diverse. Typical articles explore lipidology as it is practiced in the treatment setting, recent developments in pharmacological research, reports of treatment and trials, case studies, the impact of lifestyle modification, and similar academic material of interest to the practitioner. While preference is given to material of immediate practical concern, the science that underpins lipidology is forwarded by expert contributors so that evidence-based approaches to reducing cardiovascular and coronary heart disease can be made immediately available to our readers. Sections of the Journal will address pioneering studies and the clinicians who conduct them, case studies, ethical standards and conduct, professional guidance such as ATP and NCEP, editorial commentary, letters from readers, National Lipid Association (NLA) news and upcoming event information, as well as abstracts from the NLA annual scientific sessions and the scientific forums held by its chapters, when appropriate.